REtrospective Study of TESTIcular CAncer Patients at the University Magdeburg

Retrospective Analysis of Testicular Cancer Patients With Histopathological Analysis or Urological Treatment at the University Magdeburg 1960-2012.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02092740

Acronym

RETESTICAPUM

Enrollment

2000

Registered

2014-03-20

Start date

2012-11-30

Completion date

2012-12-31

Last updated

2014-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Testicular Cancer

Keywords

Testicular cancer

Brief summary

Retrospective analysis of treatment outcome and side effects of testicular cancer patients that had been diagnosed at the University Magdeburg from 1960 until 2012.

Detailed description

Creating an ACCESS Windows form based Data Registry for testicular cancer patients. Relevant data for testicular cancer patients based on EAU-guidelines 2013 and EORTC/RTOG, Lent-SOMA, CTC. All testicular cancer patients who had been histopathologically diagnosed al the Institute of Pathology at the University Magdeburg. About 2000 patients from 1960 until 2012. Postgraduate students collecting data requesting hospital documents, cancer registry of Sachsen-Anhalt, family practitioners and urologists as well as patients. Statistically Analysis with ACCESS and IBM SPSS statistics.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

MALE

Healthy volunteers

Inclusion criteria

* testicular cancer histopathologically diagnosed at the University Magdeburg Germany

Exclusion criteria

* none.

Design outcomes

Primary

Measure	Time frame	Description
Overall survival (OS)	Up to 52 years.	Overall survival (OS).

Secondary

Measure	Time frame	Description
Chronic side effects of testicular-cancer-specific radiation therapies.	Up to 52 years.	All Therapy Associated side effects of radiation therapy using EORTC (European Organisation for Research and Treatment of Cancer) /RTOG- (Radiation Therapy Oncology Group) - RTOG/EORTC Late Radiation Morbidity Scoring Schema), LENT-SOMA-(Late Effects of Normal Tissues)-, CTCAE-(Common Terminology Criteria for Adverse Events V4)-Scores. See
Chronic side effects of testicular-cancer-specific chemotherapies.	Up to 52 years.	All Therapy Associated side effects of chemotherapy using CTCAE-(Common Terminology Criteria for Adverse Events V4)-Score.
Chronic side effects of testicular-cancer-specific surgical therapies.	Up to 52 years.	All Therapy Associated side effects of surgical therapy using CTCAE-(Common Terminology Criteria for Adverse Events V4)-Score.
Secondary Malignoma	Up to 52 years.	Assessment of Development of Secondary malignoma after diagnosis of testicular cancer; Secondary malignoma other than testicular cancer and metachronous Primary testicular cancer
Disease-specific survival.	Up to 52 years.	Disease-specific survival of testicular cancer.
Relapse-free survival (RLS).	Up to 52 years.	Relapse-free survival (RLS).
Quality of Life (QoL).	Current situation.	Assessment of the current QoL using ECOG and EORTC-QLQ-C30-V3D.
Cause of death.	Up to 52 years.	Cause of death.
Progressive-free survival (PFS).	Up to 52 years.	Progressive-free survival (PFS).

Countries

Germany

Outcome results